Blog
RSS FeedPosted by Michael Wonder on 11 Jul 2023
Make medicines affordable - without going to court
11 July 2023 - Governments can and must take control to prevent extreme drug prices. ...
Posted by Michael Wonder on 01 May 2023
Dutch Ministry Of Health will not reimburse Gilead’s breast cancer drug, Trodelvy
1 May 2023 - Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not ...
Posted by Michael Wonder on 05 Mar 2023
Medicine and medical device pricing and reimbursement in Netherlands
2 March 2023 - Since the Netherlands is a Member State of the European Union, it has implemented the European ...
Posted by Michael Wonder on 04 Dec 2022
Anti-viral COVID-19 treatment now available in the Netherlands for 1,250 Euros
1 December 2022 - The anti-viral medication approved to treat COVID-19 is now available on the Dutch market, the Dutch Association ...
Posted by Michael Wonder on 27 Nov 2022
High demand of popular obesity drug Saxenda; may be going to "wrong" patients
26 November 2022 - Since April of this year there has been a high demand for the obesity drug Saxenda, but ...
Posted by Michael Wonder on 17 Oct 2022
Amryt receives reimbursement approval from the Dutch Ministry of Health for Myalepta (metreleptin)
17 October 2022 - Amryt receives reimbursement approval from the Dutch Ministry of Health for Myalepta (metreleptin). ...
Posted by Michael Wonder on 24 Sep 2022
Doctors, patients protest at plans to cap medicine prices
23 September 2022 - Doctors, pharmacists and patients organisations are angry about government plans to cut spending on medicine, which ...
Posted by Michael Wonder on 08 Mar 2022
Key considerations in the health technology assessment of advanced therapy medicinal products in Scotland, The Netherlands and England
8 March 2022 - Advanced therapy medicinal products are highly innovative therapies. Their costs and uncertain value claims have raised concerns ...
Posted by Michael Wonder on 13 Nov 2021
Dutch health insurance: what changes in 2022?
11 November 2021 - The Dutch healthcare institute Zorginstituut Nederland is going to increase its monitoring of treatment to better ...
Posted by Michael Wonder on 02 Sep 2021
Patients in the Netherlands wait 1.5 years for access to new medicines
2 September 2021 - Patients in the Netherlands have to wait an average of 510 days for access to a new ...
Posted by Michael Wonder on 03 Aug 2021
Hansa Biopharma announces reimbursement in the Netherlands of Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
2 August 2021 - Idefiris (imlifidase) for enabling kidney transplantation in highly sensitised patients is now reimbursable and available for use ...
Posted by Michael Wonder on 07 Jul 2020
Did a pharma trade group try to sabotage a Dutch government report on compulsory licensing?
7 July 2020 - Dutch government commission on compulsory licensing was nearly sabotaged last month after one of its members ...
Posted by Michael Wonder on 05 Feb 2020
Five pillars for societal perspective
31 January 2020 - In economic evaluation, the healthcare perspective has gradually given way to use of the societal perspective, as ...
Posted by Michael Wonder on 15 Oct 2019
DIY drugs: should hospitals make their own medicine?
15 October 2019 - If pharmaceutical companies rapidly inflate the price of their products, is there an alternative? One Dutch chemist ...
Posted by Michael Wonder on 02 Sep 2019
Dutch experience demonstrates effective benchmarking of biosimilar use in health systems
31 August 2019 - As medicines become more numerous and often more expensive, health care professionals seek new ways to understand ...